X0306 4 2021-01-07 0 0001801170 CLOVER HEALTH INVESTMENTS, CORP. /DE CLOV 0001839810 Wagner Joseph F. C/O CLOVER HEALTH INVESTMENTS, CORP. 725 COOL SPRINGS BLVD., SUITE 320 FRANKLIN TN 37067 0 1 0 0 Chief Financial Officer Stock Options (right to buy) 2.23 2021-01-07 4 A 0 517018 A 2030-02-03 Class B Common Stock 517018 517018 D Stock Options (right to buy) 5.41 2021-01-07 4 A 0 125496 A 2030-08-21 Class B Common Stock 125496 125496 D 100% of the stock option is immediately exercisable. The stock option vests as to 1/5th of the total number of shares on December 30, 2020 and 1/60th of the total number of shares in equal monthly installments thereafter, subject to the continuous service of the Reporting Person on each vesting date. The Class B Common Stock will be convertible into shares of Class A Common Stock on a one-to-one basis at the option of the holders of the Class B Common Stock at any time upon written notice to the Issuer. In addition, the Class B Common Stock will automatically convert into shares of Class A Common Stock immediately prior to the close of business on the earliest to occur of certain events specified in the Issuer's Amended and Restated Certificate of Incorporation. Received in connection with the Issuer's business combination (the "Business Combination") with Clover Health Investments, Corp. ("Legacy Clover") in accordance with the terms of the Agreement and Plan of Merger dated as of October 5, 2020, among the Issuer (f/k/a Social Capital Hedosophia Holdings Corp. III), Asclepius Merger Sub Inc., and Legacy Clover, as amended by that certain Amendment to the Agreement and Plan of Merger, dated as of December 8, 2020, in exchange for options to acquire 250,000 shares of common stock of Legacy Clover for $4.61 per share. Received in connection with the Business Combination in exchange for options to acquire 60,683 shares of common stock of Legacy Clover for $11.19 per share. /s/ Gia Lee, as Attorney-in-Fact 2021-01-11